RankmyAI - Explore and track more than 63,000 AI tools

Overall Ranking

Traffic Ranking

Investment Ranking

Fallers Ranking

Ranking by Popular rankings

All rankings in Popular rankings

Sune Selsbæk-Reitz on promptism, fluent machines, and why AI makes it easier to stop thinking too soon

Sune Selsbæk-Reitz on promptism, fluent machines, and why AI makes it easier to stop thinking too soon

An interview with Sune Selsbæk-Reitz on his new book Promptism and why the real risk of AI is not in the technology itself, but in how we use it. He explains how fluent systems influence thinking, why knowledge matters more than ever, and what professionals should do to stay in control.

The Military AI Landscape in 2026: From Hardware to Software

The Military AI Landscape in 2026: From Hardware to Software

What does the military AI landscape actually look like? Drawing on data from 519 companies across 12 categories, this analysis examines where investment is flowing, which regions are leading, and why software, intelligence and coordination capabilities are becoming increasingly important.

Rankings
Insights
Maps
About Us
- Methodology
- Faq
- Careers
- Partners

Ranking August 2026

What are the top 25 AI drug discovery & development tools in August 2026?

The RankmyAI AI Drug Discovery & Development Ranking presents the top 25 AI tools from our Overall ranking in August 2026 focusing on AI drug discovery & development.

AI drug discovery tools are used to enhance and expedite the drug discovery and development process by analyzing vast datasets to identify potential drug candidates, predict their interactions, and optimize their design. They work by leveraging algorithms that can process biological data, simulate chemical interactions, and model biological systems, which aids researchers in generating insights that traditionally required more time and manual effort. Primary applications of AI in drug development include target identification, lead compound screening, and preclinical research, offering professionals powerful resources in the complex landscape of pharmaceutical development.

The green up and red down arrows indicate how many positions a tool has increased or decreased compared to the previous month's ranking. A grey dash means the tool's position has remained unchanged.

Top 25 out of

63

AISight is a cloud-native digital pathology image management system supporting AI applications for case and image management, designed for leading laboratories and research centers.

Juvenescence develops innovative medicines targeting aging mechanisms to treat and prevent age-related diseases, enhancing healthy lifespan through AI-enabled R&D and adaptive clinical trials.

Soley Therapeutics

Soley Therapeutics utilizes AI/ML to decode cellular language, enhancing drug discovery and development efficiency through a high-throughput platform technology.

Lantern Pharma leverages AI, machine learning, and genomics to revolutionize oncology drug development, significantly enhancing speed, power, precision, and cost efficiency.

Healx leverages AI to transform drug discovery for rare diseases, enhancing known compounds and identifying novel drug-disease relationships to build effective therapies.

Anagenex accelerates drug discovery using proprietary generative AI and neural networks, processing billions of compound experiments to refine predictions and deliver medicines faster with datasets over 100B datapoints.

Aqemia leverages quantum-inspired physics and AI to rapidly accelerate the drug discovery process, generating its own data to identify drug candidates with unprecedented speed and accuracy.

Noetik leverages advanced machine learning to discover and develop cancer immunotherapies, focusing on precision and patient-centered approaches.

Aignostics specializes in applying AI to precision medicine, transforming complex biomedical data to deliver insights that enhance drug development and patient outcomes. It integrates multimodal AI technologies with robust foundation models tailored for histopathology.

GT Apeiron Therapeutics

Apeiron Therapeutics is a clinical-stage biopharmaceutical company developing biomarker-driven, AI-enabled small molecule therapies for cancer. The company leverages structure-based, AI-driven drug design to build a pipeline of targeted treatments, aiming for best-in-class and first-in-class oncology candidates that address unmet medical needs.

GEn1E Lifesciences

GEn1E Lifesciences employs a machine learning-driven approach to accelerate the development of first-in-class therapies for inflammatory diseases, utilizing unique allosteric binding mechanisms to improve specificity and reduce side effects.

Makya is a generative AI platform by Iktos, designed for chemists to accelerate drug discovery using AI-driven molecular design, synthesis planning, and automation through a fully integrated pipeline.

Gero leverages physics-informed AI models to develop therapeutics targeting the root causes of aging, aiming to double human healthspan. Their platform integrates extensive real-world data to identify novel therapeutic targets and design effective interventions.

Receptor.AI accelerates drug discovery with AI-driven platforms for small molecules and peptides, integrating predictive modeling and data-driven strategies for efficient optimization.

InpharmD™ provides healthcare professionals with quick access to customized, actionable drug information, enhancing efficiency in making informed clinical decisions by transforming complex literature searches into streamlined insights.

CELLINK offers comprehensive 3D bioprinting solutions, including bioprinters and bioinks, to advance research in regenerative and personalized medicine and drug discovery.

Graphen provides advanced AI solutions harnessing graph technology, offering AI-driven tools for finance, healthcare, and more, facilitating improved decision-making and operational efficiency through comprehensive data analysis.

GenBio AI develops AI-driven digital organisms using multiscale foundation models to predict, simulate, and program biology, advancing healthcare and scientific discovery.

Novigenix AI provides LITOseek, an immuno-transcriptomics liquid biopsy platform that decodes immune response for precision oncology, enabling therapy response prediction, monitoring, and biomarker discovery.

PhAST Diagnostics uses AI and machine learning to enhance infectious disease diagnostics, focusing on antibiotic resistance with a cloud-based platform for clinical decision support and workflow improvement.

Dalton is an AI-enabled platform for drug discovery, providing cloud-native infrastructure that integrates data ingestion, model training, molecule generation, and experiment prioritization for pharma, biotech, and CROs.

Output Biosciences

Output Biosciences develops biologically-aware generative AI and Large Biological Models to understand complex biological systems and accelerate discovery of breakthrough medicines. Their architecture is designed for long, nonlinear, high-dimensional biological data, aiming to transform diagnosis, treatment, and disease prevention.

101GenAI is a healthcare-specific AI platform enabling rapid build, deployment, and scaling of multi-agent workflows with API integrations, enhancing healthcare workflows with AI capabilities.

Altay Therapeutics

Altay Therapeutics is a biotechnology company developing first- and best-in-class oral small-molecule inhibitors that directly target transcription factors. Its pipeline includes a DUX inhibitor for facioscapulohumeral muscular dystrophy (FSHD), a potent STAT inhibitor for inflammatory diseases and oncology, and additional oncology programs. The platform identifies dynamic allosteric sites to design highly selective compounds, aiming to deliver differentiated therapies for patients with limited treatment options.

Contact us for tailored rankings and in-depth research

Rankings in Healthcare

Latest insights

Why RankmyAI is the first Founding Partner of BRAIN Nederland

Why RankmyAI is the first Founding Partner of BRAIN Nederland

RankmyAI has joined BRAIN Nederland as its first Founding Partner. In an interview with BRAIN, CEO Jesse Weltevreden explains why independent market data matters and what the Dutch AI sector needs to grow up.

AI Report Denmark 2026: Danish AI, built for business

AI Report Denmark 2026: Danish AI, built for business

The first AI Report Denmark maps 1,249 Danish AI tools and companies and ranks them in five ways. Danish AI turns out to be built for organisations rather than consumers, and a small group of companies attracts most of the money. Download the full report and see where each company stands.

Disclaimer

The RankmyAI AI Drug Discovery & Development Ranking is derived from our Overall ranking, which measures the popularity of AI tools based on three key metrics: website traffic, reviews, and investments. The Overall ranking is calculated as the weighted average of the individual rankings for each of these metrics (for more details, see our Methodology page).

Not all AI tools in this ranking are exclusively focused on AI in drug discovery & development, as AI tools and companies often provide multiple services beyond this specific application. This ranking does not assess or indicate the quality, effectiveness, or reliability of the listed AI tools. It is solely based on popularity metrics and should not be interpreted as an endorsement or evaluation of their performance.

You are free to use and distribute our ranking, provided that RankmyAI is properly cited as the source (see our Copyright page).